Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the predictive value of specific neuroendocrine tests TRH-TSH and DST in how patients with major depression respond to repetitive transcranial magnetic stimulation-theta burst stimulation rTMS-TBS. This pilot study involves adults aged 18 to 65 who have major depression and have not adequately responded to two previous antidepressant treatments. The goal is to see if these tests can predict a decrease of at least 50% in depression scores after treatment. The study involves 20 sessions of rTMS-TBS delivered once daily on weekdays. This treatment uses bursts of magnetic stimulation at high frequency for about five minutes per session. Patients will be evaluated for their depression symptoms at baseline, after ten sessions, and after the full 20 sessions using the 17-item Hamilton Depression Scale. Neuroendocrine tests are performed at the start and, if abnormal initially, again at the end of the treatment. Participants will be hospitalized patients monitored by investigators who assess their depression levels while blinded to the neuroendocrine test results. Assessments occur at inclusion, mid-treatment, and end of treatment to determine response. The main outcome is the change in depression scores after six weeks. Safety and other neuroendocrine changes will also be observed. The study is conducted over about six weeks with careful clinical and laboratory monitoring throughout.
Actively Recruiting
People with mental disorders tend to smoke more than the general population, which contributes to a significant reduction in their life expectancy, mainly due to cardiovascular and respiratory diseases like bronchial cancers. Smoking cessation efforts targeting this group, especially in psychiatric care, are often insufficient. This study evaluates a new intervention called Tabapsy, designed in collaboration with mental health users, professionals, and general practitioners, aimed at helping adults receiving outpatient psychiatric care reduce or quit smoking. The Tabapsy intervention includes a campaign promoting smoking cessation within psychiatric medical psychological centers CMPs and a structured program to support quitting. This program involves a general information meeting to encourage motivation, an assessment workshop to personalize cessation plans based on nicotine dependence, five thematic workshops addressing treatments, emotional management, weight gain, physical activities, and manual occupations, plus peer support groups to foster mutual aid. A facilitator leads these workshops, and a website complements the resources provided. The trial compares this intervention against usual smoking cessation practices in randomized psychiatric sectors. Participants who regularly smoke and agree to join will complete questionnaires at the start, 3 months, and 6 months, assessing tobacco use, dependence, motivation, well-being, knowledge, and satisfaction. The study will measure short-term smoking cessation at 3 months as the primary outcome, along with various secondary outcomes including motivation, quit attempts, mental and physical well-being, cost-effectiveness, and implementation success. The trial plans to include 6,250 participants over 12 months and will combine quantitative and qualitative evaluations.